Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Renal Cell 11Sarcoma 6Neoplasms 6Lymphoma, Mantle-Cell 6Prostatic Neoplasms 5Lymphoma, Non-Hodgkin 5Rhabdomyosarcoma 4Neoplasm Metastasis 4Kidney Neoplasms 4Gliosarcoma 4Glioblastoma 4Breast Neoplasms 4Brain Neoplasms 4Waldenstrom Macroglobulinemia 3Osteosarcoma 3Melanoma 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Endometrial Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Oligodendroglioma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Liposarcoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Glioma 2Fallopian Tube Neoplasms 2Carcinoma, Hepatocellular 2

Interventions

sargramostim 3dinutuximab 3Vincristine 3Topotecan 3Stem Cell Transplantation 3Radiation 3Platinum 3Melphalan 3Isotretinoin 3Doxorubicin 3Cyclophosphamide 3Congresses as Topic 3Colony-Stimulating Factors 3Cisplatin 31,2-diaminocyclohexaneplatinum II citrate 3Temozolomide 2Irinotecan 2Etoposide 2Busulfan 23-Iodobenzylguanidine 2temsirolimus 1etoposide phosphate 1Thiotepa 1Specimen Handling 1Sirolimus 1Razoxane 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Peripheral Blood Stem Cell Transplantation 1Mesna 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Ganglioneuroblastoma × temsirolimus × Clear all
NCT01767194 2022-10-24

Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma

National Cancer Institute (NCI)

Phase 2 Completed
73 enrolled 12 charts
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡